Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that there will be a small but healthy amount of growth in the biologics market for the treatment of psoriatic arthritis. According to the new report entitled Favorable Environment for Biologics Will Lead to Profits in Emerging Markets: A Psoriatic Arthritis Study, Amgen/Wyeth/Takeda's Enbrel will remain the leader among biologic therapies through 2015, with Abbott/Eisai's Humira being a strong competitor.

The currently marketed biologics for psoriatic arthritis, Enbrel, Humira, and Centocor/Schering-Plough/Tanabe's Remicade, have seized the substantial opportunity present in the undertreated psoriatic arthritis market. Decision Resources' analysis involving clinical trial data and primary research with thought leaders and rheumatologists reveals that these biologics demonstrate efficacy that surpasses that of the traditional small-molecule therapies. Furthermore, only biologic therapies are effective in treating spinal involvement, which can occur in up to 40% of psoriatic arthritis patients. As a result, biologic agents garner a larger patient share and often enjoy less- restrictive reimbursement for psoriatic arthritis than for the more widely known arthropathy, rheumatoid arthritis.

"Psoriatic arthritis is under-recognized, but there is an effort underway to increase physician awareness," said Joanna Kim, analyst at Decision Resources. "Growth in this market will increase as disease awareness and diagnosis rates increase. Small-molecule therapies work well for the treatment of rheumatoid arthritis, but they have questionable or poor efficacy rates in the treatment of psoriatic arthritis. Biologics offer both the efficacy rates and the long-term safety needed to rival the conventional disease-modifying antirheumatic drugs in treatment decisions for psoriatic arthritis."

About Favorable Environment for Biologics Will Lead to Profits in Emerging Markets

  Favorable Environment for Biologics Will Lead to Profits in Emerging   Markets: A Psoriatic Arthritis Study covers the current and future state   of the psoriatic arthritis drug market. The report includes the following:   -- More than 3,000 physician responses that define drug attributes that      drive prescription now and in the future.      -- Clinical end point tradeoffs that are most influential to         physicians.      -- Areas of unmet need with highest potential.      -- Benchmark trial results for specific drug opportunities.      -- Patient share potential for emerging therapies and target product         profiles.   -- Decision Resources proprietary analysis of commercial factors that      accelerate or constrain a drug's market potential.      -- Promotion: DTC spend, detailing intensity.      -- Reimbursement: formulary tier, prior approval restriction, quantity         limits.      -- Labeling: black box warnings, approved patient segments,         contraindications.      -- Competition: order of entry, pricing, generic entry, pipeline sales         forecast.      -- Medical practice: decision trees, treating physician type, line of         therapy.   -- Comparisons of the key clinical attributes of current and emerging      therapies in the areas of efficacy, safety, and delivery.   -- Analysis and supporting data that identify the clinical "Gold Standard"      now and over the next ten years.   -- Key insights as to which clinical end points have the greatest      influence on physician decision-making.  

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc., (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.,

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Fosamax and Actonel Primarily Prescribed as First-Line Therapy to New Osteoporosis Patients

View Now